177 related articles for article (PubMed ID: 38315168)
1. Variability in plasma rifampicin concentrations and role of
Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
Infect Dis (Lond); 2024 Apr; 56(4):308-319. PubMed ID: 38315168
[TBL] [Abstract][Full Text] [Related]
2. Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.
Mukonzo JK; Kengo A; Kutesa B; Nanzigu S; Pohanka A; McHugh TD; Zumla A; Aklillu E
Trans R Soc Trop Med Hyg; 2020 Feb; 114(2):107-114. PubMed ID: 31789383
[TBL] [Abstract][Full Text] [Related]
3. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
4. Effect of Genetic Variation of
Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
[TBL] [Abstract][Full Text] [Related]
5. SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.
Perea-Jacobo R; Muñiz-Salazar R; Laniado-Laborín R; Zenteno-Cuevas R; Cabello-Pasini A; Ochoa-Terán A; Radilla-Chávez P
Tuberculosis (Edinb); 2022 Sep; 136():102248. PubMed ID: 36055153
[TBL] [Abstract][Full Text] [Related]
6. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
Jiang F; Choi JY; Lee JH; Ryu S; Park ZW; Lee JG; Na HS; Lee SY; Oh WY; Chung MW; Choi SE
Pharmacogenomics; 2017 Apr; 18(5):459-469. PubMed ID: 28350522
[TBL] [Abstract][Full Text] [Related]
7. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
8. Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
Naidoo A; Chirehwa M; Ramsuran V; McIlleron H; Naidoo K; Yende-Zuma N; Singh R; Ncgapu S; Adamson J; Govender K; Denti P; Padayatchi N
Pharmacogenomics; 2019 Mar; 20(4):225-240. PubMed ID: 30767706
[TBL] [Abstract][Full Text] [Related]
9. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
[TBL] [Abstract][Full Text] [Related]
10. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
11. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
12. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
Phaisal W; Albitar O; Chariyavilaskul P; Jantarabenjakul W; Wacharachaisurapol N; Ghadzi SMS; Zainal H; Harun SN
J Antimicrob Chemother; 2024 Jun; 79(6):1270-1278. PubMed ID: 38661209
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
15. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
[TBL] [Abstract][Full Text] [Related]
16. Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis.
Kim ES; Kwon BS; Park JS; Chung JY; Seo SH; Park KU; Song J; Yoon S; Lee JH
Br J Clin Pharmacol; 2021 Sep; 87(9):3492-3500. PubMed ID: 33538008
[TBL] [Abstract][Full Text] [Related]
17. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.
Medellin-Garibay SE; Huerta-García AP; Rodríguez-Báez AS; Magaña-Aquino M; Ortiz-Álvarez A; Portales-Pérez DP; Milán-Segovia RDC; Romano-Moreno S
Tuberculosis (Edinb); 2020 Sep; 124():101982. PubMed ID: 32810723
[TBL] [Abstract][Full Text] [Related]
18. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
19. Effects of rifampicin,
Zhang L; Meng X; Dong P; Qi T; Liu L; Wang B
Int J STD AIDS; 2023 Jan; 34(1):37-47. PubMed ID: 36356965
[TBL] [Abstract][Full Text] [Related]
20. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]